Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Small Cell 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × EC regimen × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Shanghai Henlius Biotech

Phase 3 Active not recruiting
200 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡